background
neuraminidas
inhibitor
thought
efficaci
reduc
time
allevi
symptom
outpati
season
influenza
object
studi
compar
shortterm
virolog
efficaci
oseltamivirzanamivir
combin
versu
monotherapi
plu
placebo
conduct
random
placebocontrol
trial
gener
practition
throughout
franc
season
influenza
epidem
patient
gener
practition
outcom
assessor
blind
treatment
assign
adult
outpati
present
influenzalik
ill
less
hour
posit
influenza
rapid
test
diagnosi
random
oseltamivir
mg
oral
twice
daili
plu
zanamivir
mg
inhal
twice
daili
oz
oseltamivir
plu
inhal
placebo
zanamivir
plu
oral
placebo
z
treatment
efficaci
assess
virolog
accord
proport
patient
nasal
influenza
revers
transcript
rt
pcr
copi
genom
equival
cgeq
ml
day
primari
outcom
clinic
time
allevi
symptom
day
overal
patient
plan
includ
oz
n
n
z
n
male
mean
age
year
intentiontotreat
analysi
conduct
patient
rtpcrconfirm
influenza
oz
n
n
z
n
arm
cgeqml
confid
interv
ci
p
ci
p
ozo
ozz
comparison
mean
day
day
viral
load
decreas
log
cgeqml
p
p
ozo
ozz
median
time
allevi
symptom
day
ci
p
ci
p
ozo
ozz
four
sever
advers
event
observ
nausea
andor
vomit
tend
frequent
combin
arm
oz
n
n
z
n
patient
respect
conclus
adult
season
influenza
mainli
viru
infect
oseltamivirzanamivir
combin
appear
less
effect
oseltamivir
monotherapi
significantli
effect
zanamivir
monotherapi
despit
theoret
potenti
reduct
emerg
antivir
resist
lower
effect
combin
call
caution
use
clinic
practic
neuraminidas
inhibitor
oseltamivir
zanamivir
z
thought
efficaci
compar
placebo
outpati
uncompl
season
influenza
clinic
term
reduct
durat
symptom
well
term
reduct
viral
shed
consid
import
strategi
limit
impact
influenza
pandem
individu
reduc
morbid
mortal
collect
slow
spread
viru
allow
time
vaccin
product
cornerston
influenza
control
hypothes
widespread
use
singl
antivir
might
result
emerg
resist
strain
whose
subsequ
spread
could
dramat
reduc
effect
antivir
therapi
combin
two
antivir
agent
well
toler
produc
least
addit
antivir
activ
theoret
offer
sever
advantag
reduc
diseas
sever
viral
shed
viral
excret
period
therebi
also
lower
attack
rate
risk
select
resist
virus
specif
individu
prolong
viral
shed
immunocompromis
patient
inde
mathemat
model
show
reduct
risk
emerg
resist
strain
earli
phase
pandem
associ
use
two
antivir
compar
singl
antivir
therapi
final
anoth
theoret
advantag
combin
two
drug
would
ensur
optim
treatment
circul
influenza
viru
type
subtyp
variant
suscept
influenza
virus
shown
vari
season
virus
natur
resist
oseltamivir
remain
suscept
zanamivir
emerg
among
antivir
activ
influenza
viru
combin
neuraminidas
inhibitor
attract
compound
licens
season
influenza
deliv
respiratori
tract
distinct
mean
directli
diskhal
zanamivir
gastrointestin
absorpt
hepat
metabol
oseltamivir
key
mutat
associ
resist
differ
drug
howev
neg
interact
rule
owe
possibl
competit
two
drug
target
bind
pocket
neuraminidas
context
pandem
plan
design
doubleplacebo
random
control
trial
patient
present
season
influenzalik
ill
compar
oseltamivirzanamivir
combin
monotherapi
plu
placebo
trial
conduct
franc
winter
emerg
pandem
viru
human
april
north
america
subsequ
worldwid
spread
independ
datamonitor
committe
request
termin
trial
earli
analyz
result
earlier
plan
given
possibl
impact
result
antivir
treatment
manag
pandem
januari
march
period
winter
influenza
epidem
franc
enrol
throughout
franc
adult
old
older
consult
gener
practition
within
h
influenza
symptom
onset
follow
first
influenza
symptom
report
patient
temperatur
greater
equal
report
observ
practition
one
respiratori
symptom
cough
sore
throat
one
gener
symptom
headach
dizzi
myalgia
sweat
chill
fatigu
posit
nasal
rapid
test
influenza
clearview
exact
influenza
b
perform
practition
enrol
women
requir
neg
urin
pregnanc
test
exclus
criteria
vaccin
influenza
season
recent
exacerb
chronic
obstruct
pulmonari
diseas
copd
asthma
sever
chronic
diseas
previou
histori
depress
prior
inclus
trial
prior
inclus
patient
gave
inform
written
consent
protocol
approv
ethic
committe
ile
de
franc
text
enrol
day
nasal
swab
virolog
analysi
perform
use
standard
oper
procedur
sampl
kit
plu
instruct
video
patient
alloc
treatment
random
list
arm
ratio
balanc
practition
comput
random
number
gener
use
select
random
permut
block
size
randomis
code
given
central
hospit
pharmaci
prepar
blind
treatment
unit
conform
good
manufactur
practic
gmp
gener
practition
receiv
six
treatment
unit
told
distribut
order
inclus
patient
trial
alloc
conceal
similar
contain
imposs
gp
identifi
treatment
arm
open
contain
three
treatment
oseltamivir
capsul
oral
use
plu
inhal
zanamivir
oseltamivir
plu
inhal
placebo
zanamivir
plu
oral
placebo
oseltamivir
dosag
mg
oral
twice
daili
zanamivir
dosag
mg
oral
inhal
use
commerci
glaxosmithklin
diskhal
twice
daili
activ
drug
placebo
kindli
provid
roch
glaxosmithklin
laboratori
visit
nurs
perform
nasal
swab
virolog
analysi
day
patient
return
gener
practition
day
followup
examin
contact
phone
day
patient
gener
practition
assign
patient
outcom
assessor
practition
virologist
patient
blind
treatment
assign
throughout
studi
statistician
end
analysi
nasal
swab
place
transport
medium
virocult
elitech
transport
special
courier
nearest
nation
influenza
centr
nic
hospic
civil
de
lyon
lyon
pasteur
institut
pari
franc
upon
arriv
swab
sampl
elut
ml
transport
medium
process
realtim
revers
transcript
rt
pcr
analys
inocul
onto
mdck
cell
viru
isol
subsequ
subtyp
use
standard
hemagglutin
inhibit
assay
rtpcr
analys
rna
extract
ml
specimen
perform
use
qiamp
viru
rna
mini
kit
qiagen
rna
elut
final
volum
ml
realtim
rtpcr
assay
perform
final
volum
ml
ml
rna
mm
primer
mm
probe
ml
enzym
mix
superscriptiii
platinum
onestep
quantit
rtpcr
system
invitrogen
type
influenza
viru
rna
detect
realtim
rtpcr
target
conserv
matrix
gene
use
gram
primer
gram
fam
tcaggcc
cctcaaagccgag
probe
qualiti
specimen
assess
realtim
rtpcr
target
gapdh
cellular
gene
amplif
perform
lightcycl
roch
diagnost
nic
pasteur
institut
pari
abi
appli
biosystem
nic
lyon
cycl
condit
avail
upon
request
quantifi
synthet
rna
transcript
correspond
gapdh
gene
use
control
parallel
take
account
variabl
quantiti
cell
collect
nasal
swab
calcul
normal
influenza
viral
load
specimen
normal
viral
load
defin
ratio
rtpcr
gapdh
rtpcr
multipli
averag
gapdh
rtpcr
day
express
result
copi
genom
equivalentml
cgeqml
virolog
respons
defin
normal
viral
load
cgeqml
day
threshold
determin
accord
result
specimen
patient
posit
influenza
rapid
test
winter
includ
french
influenza
surveil
network
grog
analys
result
fals
posit
fals
neg
result
respect
viru
isol
tabl
valid
independ
datamonitor
committe
prior
analysi
sensit
qrtpcr
assess
use
serial
dilut
quantifi
synthet
transcript
correspond
target
gene
text
assess
compar
data
two
nic
specimen
exchang
show
excel
concord
threshold
qrtpcr
use
set
well
limit
detect
oral
temperatur
record
sever
seven
symptom
nasal
stuffi
sore
throat
cough
muscl
ach
tired
fatigu
headach
feverish
rate
patient
twice
daili
morn
even
day
daili
fourpoint
scale
none
mild
moder
sever
time
resolut
ill
defin
time
studi
drug
initi
time
symptom
allevi
symptom
allevi
defin
first
period
seven
symptom
absent
mild
previous
describ
influenzarel
clinic
event
defin
incid
secondari
complic
pneumon
otiti
independ
antibiot
initi
andor
occurr
exacerb
preexist
chronic
diseas
patient
report
treatment
complianc
use
selfadminist
questionnair
full
complianc
day
day
period
consid
plan
drug
intak
complet
primari
efficaci
endpoint
proport
patient
cgeqml
day
treatment
given
viral
shed
kinet
patient
season
influenza
receiv
neuraminidas
inhibitor
day
virolog
endpoint
consid
best
suit
measur
virolog
effect
endpoint
decreas
log
viral
load
day
patient
confirm
influenza
day
avail
sampl
day
time
resolut
ill
number
patient
allevi
symptom
end
treatment
day
symptom
score
end
treatment
incid
secondari
complic
influenza
otiti
bronchiti
sinus
pneumonia
use
antibiot
occurr
advers
event
particip
receiv
least
one
dose
accord
protocol
intentiontotreat
itt
analysi
perform
two
popul
enrol
patient
primari
object
enrol
patient
influenza
viru
infect
confirm
rtpcr
day
influenza
ainfect
popul
sampl
size
evalu
assum
virolog
respons
obtain
patient
oseltamivirzanamivir
arm
compar
monotherapi
arm
basi
extrapol
result
previou
trial
sampl
subject
per
arm
power
detect
differ
twosid
test
type
error
two
test
factor
lack
followup
proport
respons
day
compar
combin
therapi
arm
oz
monotherapi
arm
z
separ
use
two
test
type
error
two
test
patient
without
day
sampl
consid
treatment
failur
mean
decreas
log
viral
load
compar
use
ttest
patient
day
day
sampl
assum
valu
cgeqml
rtpcr
neg
clinic
endpoint
nonparametr
test
use
time
resolut
ill
symptom
score
end
treatment
compar
use
wilcoxon
test
time
symptom
allevi
miss
imput
ie
end
trial
confid
interv
ci
median
differ
estim
bootstrap
probabl
symptom
allevi
versu
day
treatment
estim
use
kaplan
meier
method
compar
group
logrank
test
proport
clinic
event
patient
allevi
symptom
compar
use
fisher
exact
test
exploratori
analysi
ci
differ
respons
two
monotherapi
also
estim
analys
perform
use
sa
softwar
version
sa
institut
patient
initi
plan
total
patient
enrol
gener
practition
randomli
assign
oseltamivir
plu
zanamivir
oz
n
oseltamivir
plu
inhal
placebo
n
zanamivir
plu
oral
placebo
z
n
figur
mean
age
standard
deviat
sd
male
preexist
chronic
diseas
mean
fever
sd
mean
durat
ill
enrol
h
sd
characterist
patient
appear
well
balanc
three
arm
tabl
rate
fulli
compliant
patient
significantli
differ
among
three
arm
oz
arm
arm
z
arm
enrol
patient
rtpcr
laboratori
confirm
influenza
viru
infect
day
specimen
mean
viral
load
log
cgeqml
interquartil
rang
iqr
day
specimen
gapdh
rtpcr
posit
mean
valu
log
copiesml
primari
endpoint
itt
analysi
consid
enrol
patient
posit
influenza
rapid
test
proport
patient
cgeqml
day
treatment
oseltamivirzanamivir
arm
oseltamivir
monotherapi
arm
p
tabl
trend
observ
fulli
compliant
influenza
ainfect
patient
tabl
patient
infect
proport
oseltamivirzanamivir
arm
oseltamivir
monotherapi
arm
zanamivir
monotherapi
arm
virolog
endpoint
influenza
rtpcr
confirm
patient
day
day
avail
specimen
day
day
decreas
log
cgeqml
oseltamivirzanamivir
arm
log
median
time
resolut
ill
enrol
patient
sum
sever
seven
day
influenza
symptom
feverish
nasal
stuffi
sore
throat
cough
muscl
ach
tirednessfatigu
headach
use
fourpoint
scale
b
score
express
percentag
maxim
score
tabl
clinic
outcom
show
similar
trend
tabl
four
seriou
advers
event
occur
studi
one
consid
unrel
studi
drug
acut
bacteri
pneumonia
day
patient
receiv
oseltamivirzanamivir
combin
two
advers
event
also
occur
patient
receiv
oseltamivirzanamivir
combin
sever
headach
lead
interrupt
therapi
facial
oedema
follow
first
administr
disappear
within
h
postdrug
interrupt
remain
patient
experienc
repeat
vomit
oseltamivir
monotherapi
drug
administr
four
patient
complet
recov
nonseri
advers
event
report
total
popul
oz
z
arm
respect
nausea
andor
vomit
patient
diarrhoea
patient
rash
patient
larg
publicli
fund
clinic
trial
examin
effect
combin
neuraminidas
inhibitor
antivir
therapi
influenza
compar
monotherapi
plu
placebo
show
prepandem
winter
predomin
virus
franc
oseltamivirzanamivir
combin
seem
less
effect
oseltamivir
monotherapi
significantli
effect
zanamivir
monotherapi
adult
season
influenza
viru
infect
analysi
differ
antivir
regimen
efficaci
base
primari
virolog
endpoint
hypothes
could
sensit
specif
indic
primari
clinic
endpoint
clinic
endpoint
use
primari
endpoint
previou
studi
use
secondari
endpoint
present
studi
clinic
endpoint
base
global
assess
gener
mainli
immunolog
link
respiratori
mainli
virolog
link
symptom
probabl
best
way
monitor
virolog
effect
treatment
clinic
symptom
exclus
influenza
thu
consid
differ
viral
shed
rate
would
best
indic
virolog
effect
combin
therapi
consequ
valuabl
surrog
initi
hypothesi
combin
two
antivir
may
reduc
rate
resist
viru
emerg
natur
suscept
pandem
viru
nonimmun
popul
addit
hypothes
case
infect
suscept
season
influenza
virus
could
easili
shown
owe
first
rariti
phenomenon
adult
second
necess
monitor
viru
excret
sever
day
wherea
case
influenza
due
virus
natur
resist
oseltamivir
question
relev
given
viral
shed
kinet
patient
season
influenza
receiv
neuraminidas
inhibitor
day
virolog
endpoint
consid
best
suit
quantifi
virolog
effect
cgeql
threshold
chosen
best
compromis
term
specif
sensit
compar
standard
cultur
note
trend
observ
cgeql
cgeqml
cutoff
use
defin
virolog
success
tabl
furthermor
studi
design
statist
twosid
take
account
possibl
combin
would
perform
wors
either
drug
alon
theoret
concern
antagon
receptor
level
oseltamivirzanamivir
combin
seem
virolog
clinic
significantli
less
effect
oseltamivir
monotherapi
result
seem
robust
found
use
doubleblind
placebo
methodolog
overal
concord
among
virolog
endpoint
virolog
clinic
endpoint
confirm
three
differ
subgroup
subject
includ
global
popul
enrol
patient
influenza
ainfect
patient
influenza
ainfect
fulli
compliant
patient
lower
clinic
virolog
respons
combin
may
suggest
neg
effect
zanamivir
oseltamivir
absenc
interact
effect
combin
least
addit
neg
interact
level
bind
catalyt
pocket
neuraminidas
explan
investig
vitro
season
virus
recent
vitro
data
show
lack
synergi
oseltamivir
zanamivir
antagon
higher
concentr
zanamivir
pandem
viru
agreement
hypothesi
furthermor
contrari
oseltamivir
upon
digest
absorpt
need
metabol
thu
delay
arriv
activ
drug
infect
site
max
h
inhal
zanamivir
deliv
directli
primari
site
influenza
viru
replic
hypothesi
zanamivir
like
occupi
catalyt
pocket
first
thu
prevent
action
oseltamivir
must
test
accord
hypothesi
combin
would
larg
reduc
zanamivir
monotherapi
wherea
result
primari
virolog
endpoint
indic
superior
oseltamivirzanamivir
combin
zanamivir
monotherapi
clinic
result
significantli
differ
suggest
oseltamivir
add
essenti
noth
zanamivir
monotherapi
view
concord
hypothesi
predomin
catalyt
site
occup
zanamivir
combin
administ
exploratori
analysi
oseltamivir
show
significantli
higher
clinic
virolog
efficaci
compar
zanamivir
find
could
consequ
suboptim
treatment
regimen
zanamivir
arm
sinc
valu
virus
season
higher
zanamivir
compar
oseltamivir
remain
within
rang
suscept
strain
grog
surveil
nic
unpublish
data
virolog
result
confirm
longer
time
tabl
virolog
clinic
respons
accord
treatment
arm
influenza
ainfect
patient
day
day
itt
analysi
allevi
influenza
symptom
patient
receiv
zanamivir
present
studi
conduct
pandem
influenza
season
virus
predomin
impact
prepandem
season
oseltamivirresist
virus
result
expect
neglig
observ
trend
exclud
patient
infect
season
popul
note
virus
date
sensit
drug
remain
determin
extent
present
result
extrapol
suscept
virus
subtyp
eg
particular
pandem
viru
display
signific
differ
catalyt
pocket
neuraminidas
mix
viral
season
cocircul
virus
must
acknowledg
sever
limit
studi
first
preliminari
analysi
conduct
partial
set
data
enrol
patient
instead
initi
plan
howev
highli
unlik
lower
respons
combin
compar
oseltamivir
would
revers
origin
plan
patient
enrol
second
previou
random
clinic
trial
shown
superior
monotherapi
compar
placebo
term
time
symptom
allevi
viral
shed
decid
basi
ethic
reason
studi
would
compris
doubl
placebo
arm
third
proport
patient
unavail
viral
swab
day
higher
combin
arm
miss
valu
equal
failur
may
bias
result
combin
arm
toward
reduc
perform
inde
analysi
patient
avail
day
day
nasal
swab
trend
observ
fourth
virolog
respons
assess
one
site
nose
one
time
day
prevent
extrapol
result
entir
virolog
respons
time
throughout
respiratori
tract
howev
clinic
endpoint
complet
pictur
give
inform
overal
respons
fifth
mention
day
sampl
chosen
show
virolog
effect
howev
probabl
best
moment
look
resist
emerg
induc
drug
select
pressur
shown
occur
later
cours
treatment
nevertheless
look
neuraminidas
inhibitor
resist
use
standard
fluorimetr
test
patient
day
posit
viral
cultur
none
carri
resist
viru
except
one
patient
infect
viru
resist
oseltamivir
suscept
zanamivir
virus
circul
studi
period
howev
absenc
resist
day
rule
postday
resist
select
final
trial
conduct
adult
outpati
prevent
extrapol
result
adult
sever
present
necessit
hospitalis
children
usual
prolong
viral
shed
chose
outpati
adult
popul
seem
homogen
easiest
test
hypothesi
despit
theoret
potenti
reduct
emerg
antivir
resist
lower
effici
oseltamivirzanamivir
combin
found
studi
call
caution
use
clinic
practic
thu
also
consid
superior
oseltamivir
monotherapi
zanamivir
monotherapi
observ
trial
oseltamivir
recommend
primari
antiinfluenza
treatment
influenza
season
predomin
virus
natur
suscept
oseltamivir
result
would
need
confirm
pandem
viru
come
year
futur
circul
influenza
virus
tabl
proport
fals
posit
fals
neg
result
variou
viral
load
threshold
compar
viral
isol
sampl
grog
patient
